scholarly journals Improvement of Atopic Dermatitis by Human Sebaceous Fatty Acids and Related Lipids

Author(s):  
Hiroyuki Araki ◽  
Yoshiya Sugai ◽  
Hirofumi Takigaw
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Weng Sheng Kong ◽  
Naohiro Tsuyama ◽  
Hiroko Inoue ◽  
Yun Guo ◽  
Sho Mokuda ◽  
...  

AbstractBreastfeeding influences the immune system development in infants and may even affect various immunological responses later in life. Breast milk provides a rich source of early nutrition for infant growth and development. However, the presence of certain compounds in breast milk, related to an unhealthy lifestyle or the diet of lactating mothers, may negatively impact infants. Based on a cohort study of atopic dermatitis (AD), we find the presence of damage-associated molecular patterns (DAMPs) activity in the mother’s milk. By non-targeted metabolomic analysis, we identify the long-chain saturated fatty acids (LCSFA) as a biomarker DAMPs (+) breast milk samples. Similarly, a mouse model in which breastfed offspring are fed milk high in LCSFA show AD onset later in life. We prove that LCSFA are a type of damage-associated molecular patterns, which initiate a series of inflammatory events in the gut involving type 3 innate lymphoid cells (ILC3s). A remarkable increase in inflammatory ILC3s is observed in the gut, and the migration of these ILC3s to the skin may be potential triggers of AD. Gene expression analysis of ILC3s isolated from the gut reveal upregulation of genes that increase ILC3s and chemokines/chemokine receptors, which may play a role in ILC migration to the skin. Even in the absence of adaptive immunity, Rag1 knockout mice fed a high-LCSFA milk diet develop eczema, accompanied by increased gut ILC3s. We also present that gut microbiota of AD-prone PA milk-fed mice is different from non-AD OA/ND milk-fed mice. Here, we propose that early exposure to LCSFAs in infants may affect the balance of intestinal innate immunity, inducing a highly inflammatory environment with the proliferation of ILC3s and production of interleukin-17 and interleukin-22, these factors may be potential triggers or worsening factors of AD.


2018 ◽  
Vol 141 (2) ◽  
pp. AB131 ◽  
Author(s):  
Le Duc Huy Ta ◽  
James Chun Yip Chan ◽  
Chiung-Hui Huang ◽  
Gaik Chin Yap ◽  
Lynette Pei-Chi Shek ◽  
...  

2019 ◽  
Vol 24 (8) ◽  
pp. 400-407
Author(s):  
Sue Paterson

Therapy for canine atopic dermatitis can be described as foundation or supplementary. Foundation therapy, which refers to allergen-specific immunotherapy, ciclosporin, glucocorticoids, lokivetmab and oclacitinib, is needed in all but the mildest of cases of canine atopic dermatitis. Supplementary therapies include drugs such as antihistamines, essential fatty acids, topical therapy and other systemic anti-inflammatory drugs. While it is uncommon for any of these supplementary drugs to provide adequate control of many cases of canine atopic dermatitis, they can reduce the frequency of relapse and reduce the amount of foundation therapy that is required when used in combination with them.


2004 ◽  
Vol 45 (6) ◽  
pp. 293-297 ◽  
Author(s):  
R. S. Mueller ◽  
K. V. Fieseler ◽  
M. J. Fettman ◽  
S. Zabel ◽  
R. A. W. Rosychuk ◽  
...  

2011 ◽  
Vol 2011 (1) ◽  
Author(s):  
Albino Barraza-Villarreal ◽  
Consuelo Escamilla-Nuñez ◽  
Leticia Hernandez-Cadena ◽  
Peter Sly ◽  
Juan A. Rivera ◽  
...  

2013 ◽  
Vol 22 (4) ◽  
pp. 272-277 ◽  
Author(s):  
Masanori Fujii ◽  
Hiroyuki Nakashima ◽  
Junko Tomozawa ◽  
Yuki Shimazaki ◽  
Chie Ohyanagi ◽  
...  

2010 ◽  
Vol 3 (4) ◽  
pp. 407-417
Author(s):  
Tereshchenko Sergey Yu.; ◽  
◽  
Prahin Efim I. ◽  
Novitzkiy Ivan A. ◽  
Tzhai Vitaly B. ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document